Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption

Edward Neuwelt, Kristin Knight, Cynthia Lacy, H. Stacy Nicholson, Dale Kraemer, Nancy Doolittle, Gregory W. Hornig, Leslie Muldoon

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose. To assess the safety of delayed high dose intravenous (i.v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD). Methods. Twelve children ages 17 months-12 years underwent a total of 132 BBBD chemotherapy treatments and also received delayed high dose STS (i.V.). Dose 1 of STS (10-16 g/m2) was administered 2 or 4 hr after carboplatin, and a second STS dose was administered 4 hr after dose 1 if the child had impaired baseline hearing. Toxicity data were graded in accordance with the National Cancer Institute Common Toxicity Criteria (Version 2). Audiologic monitoring to evaluate the otoprotective potential of STS was performed on 11 children. Ototoxicity was defined in accordance with the American Speech-Language-Hearing Association (ASHA) criteria. Baseline and end of treatment hearing status were graded using Brock's criteria. Results. Nausea and vomiting were well controlled with anti-emetics administered approximately 30 min prior to STS infusion. Analogous to results in adult patients, there was mild transient hypernatremia and a trend for improved protection from ototoxicity in children who received STS delayed to 4 hr post-treatment versus 2 hr. Tumor responses were seen in heavily pre-treated patients with relatively chemo-resistant tumors, suggesting that STS did not protect the tumor from platinum cytotoxicity. Conclusion, High dose STS is well tolerated in children under 12 years of age. Further studies of STS in children are warranted to assess otoprotection and the impact of STS on platinum mediated efficacy.

Original languageEnglish (US)
Pages (from-to)174-182
Number of pages9
JournalPediatric Blood and Cancer
Volume47
Issue number2
DOIs
StatePublished - Aug 2006

Fingerprint

Carboplatin
Blood-Brain Barrier
Platinum
Hearing
American Speech-Language-Hearing Association
sodium thiosulfate
Hypernatremia
Neoplasms
Antiemetics
National Cancer Institute (U.S.)
Brain Neoplasms
Nausea
Vomiting
Therapeutics
Safety
Drug Therapy

Keywords

  • Blood brain barrier
  • Carboplatin
  • Ototoxicity
  • Pediatric brain tumor
  • Sodium thiosulfate

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. / Neuwelt, Edward; Knight, Kristin; Lacy, Cynthia; Nicholson, H. Stacy; Kraemer, Dale; Doolittle, Nancy; Hornig, Gregory W.; Muldoon, Leslie.

In: Pediatric Blood and Cancer, Vol. 47, No. 2, 08.2006, p. 174-182.

Research output: Contribution to journalArticle

@article{fcb18516c5a94b9dad3ca1c40c414ca9,
title = "Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption",
abstract = "Purpose. To assess the safety of delayed high dose intravenous (i.v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD). Methods. Twelve children ages 17 months-12 years underwent a total of 132 BBBD chemotherapy treatments and also received delayed high dose STS (i.V.). Dose 1 of STS (10-16 g/m2) was administered 2 or 4 hr after carboplatin, and a second STS dose was administered 4 hr after dose 1 if the child had impaired baseline hearing. Toxicity data were graded in accordance with the National Cancer Institute Common Toxicity Criteria (Version 2). Audiologic monitoring to evaluate the otoprotective potential of STS was performed on 11 children. Ototoxicity was defined in accordance with the American Speech-Language-Hearing Association (ASHA) criteria. Baseline and end of treatment hearing status were graded using Brock's criteria. Results. Nausea and vomiting were well controlled with anti-emetics administered approximately 30 min prior to STS infusion. Analogous to results in adult patients, there was mild transient hypernatremia and a trend for improved protection from ototoxicity in children who received STS delayed to 4 hr post-treatment versus 2 hr. Tumor responses were seen in heavily pre-treated patients with relatively chemo-resistant tumors, suggesting that STS did not protect the tumor from platinum cytotoxicity. Conclusion, High dose STS is well tolerated in children under 12 years of age. Further studies of STS in children are warranted to assess otoprotection and the impact of STS on platinum mediated efficacy.",
keywords = "Blood brain barrier, Carboplatin, Ototoxicity, Pediatric brain tumor, Sodium thiosulfate",
author = "Edward Neuwelt and Kristin Knight and Cynthia Lacy and Nicholson, {H. Stacy} and Dale Kraemer and Nancy Doolittle and Hornig, {Gregory W.} and Leslie Muldoon",
year = "2006",
month = "8",
doi = "10.1002/pbc.20529",
language = "English (US)",
volume = "47",
pages = "174--182",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption

AU - Neuwelt, Edward

AU - Knight, Kristin

AU - Lacy, Cynthia

AU - Nicholson, H. Stacy

AU - Kraemer, Dale

AU - Doolittle, Nancy

AU - Hornig, Gregory W.

AU - Muldoon, Leslie

PY - 2006/8

Y1 - 2006/8

N2 - Purpose. To assess the safety of delayed high dose intravenous (i.v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD). Methods. Twelve children ages 17 months-12 years underwent a total of 132 BBBD chemotherapy treatments and also received delayed high dose STS (i.V.). Dose 1 of STS (10-16 g/m2) was administered 2 or 4 hr after carboplatin, and a second STS dose was administered 4 hr after dose 1 if the child had impaired baseline hearing. Toxicity data were graded in accordance with the National Cancer Institute Common Toxicity Criteria (Version 2). Audiologic monitoring to evaluate the otoprotective potential of STS was performed on 11 children. Ototoxicity was defined in accordance with the American Speech-Language-Hearing Association (ASHA) criteria. Baseline and end of treatment hearing status were graded using Brock's criteria. Results. Nausea and vomiting were well controlled with anti-emetics administered approximately 30 min prior to STS infusion. Analogous to results in adult patients, there was mild transient hypernatremia and a trend for improved protection from ototoxicity in children who received STS delayed to 4 hr post-treatment versus 2 hr. Tumor responses were seen in heavily pre-treated patients with relatively chemo-resistant tumors, suggesting that STS did not protect the tumor from platinum cytotoxicity. Conclusion, High dose STS is well tolerated in children under 12 years of age. Further studies of STS in children are warranted to assess otoprotection and the impact of STS on platinum mediated efficacy.

AB - Purpose. To assess the safety of delayed high dose intravenous (i.v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD). Methods. Twelve children ages 17 months-12 years underwent a total of 132 BBBD chemotherapy treatments and also received delayed high dose STS (i.V.). Dose 1 of STS (10-16 g/m2) was administered 2 or 4 hr after carboplatin, and a second STS dose was administered 4 hr after dose 1 if the child had impaired baseline hearing. Toxicity data were graded in accordance with the National Cancer Institute Common Toxicity Criteria (Version 2). Audiologic monitoring to evaluate the otoprotective potential of STS was performed on 11 children. Ototoxicity was defined in accordance with the American Speech-Language-Hearing Association (ASHA) criteria. Baseline and end of treatment hearing status were graded using Brock's criteria. Results. Nausea and vomiting were well controlled with anti-emetics administered approximately 30 min prior to STS infusion. Analogous to results in adult patients, there was mild transient hypernatremia and a trend for improved protection from ototoxicity in children who received STS delayed to 4 hr post-treatment versus 2 hr. Tumor responses were seen in heavily pre-treated patients with relatively chemo-resistant tumors, suggesting that STS did not protect the tumor from platinum cytotoxicity. Conclusion, High dose STS is well tolerated in children under 12 years of age. Further studies of STS in children are warranted to assess otoprotection and the impact of STS on platinum mediated efficacy.

KW - Blood brain barrier

KW - Carboplatin

KW - Ototoxicity

KW - Pediatric brain tumor

KW - Sodium thiosulfate

UR - http://www.scopus.com/inward/record.url?scp=33745779428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745779428&partnerID=8YFLogxK

U2 - 10.1002/pbc.20529

DO - 10.1002/pbc.20529

M3 - Article

C2 - 16086410

AN - SCOPUS:33745779428

VL - 47

SP - 174

EP - 182

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -